What does HPLC run-time completeness mean on a peptide COA?
Run-time completeness is a documentary assessment of whether the recorded and evaluated data cover the analysis defined by the applicable method. Compare the method identifier and version, the intended analytical window, the detector acquisition duration, the displayed time range and the processing or integration window. The last reported peak provides an additional check, but its retention time does not define the required end of the analysis.
Separate three parts of the timetable: the separation used to assess the sample, any column-cleaning wash and any re-equilibration before the next run. A wash may be relevant to late-eluting impurities, or it may be a maintenance step outside the established reporting window. That distinction needs a method-based justification. Acquisition and integration do not automatically have to continue through re-equilibration.
For example, a 12-minute plot paired with a 16-minute instrument method is a discrepancy to clarify, not proof of an incomplete result. The final four minutes might contain reportable separation, an unreported wash or re-equilibration. If the method requires evaluation through minute 16 but acquisition ended at minute 12, the record does not cover the required window. If acquisition continued but the export was cropped, a fuller report may resolve the issue.
A flat baseline or a high area-percent result does not by itself establish adequate late-eluting coverage. Equally, a peak near the end of a plot is a reason to inspect the full trace and peak boundaries, not automatic proof of truncation.
Where does the gradient wash fit into the HPLC result?
Locate the method identifier and the timetable showing time, mobile-phase composition and flow rate. Where relevant, also review column details, temperature, detector settings and the mobile-phase additives. These conditions influence retention and the ability to distinguish components.
In reversed-phase HPLC, a higher-organic segment can help remove strongly retained material. It does not guarantee that all relevant impurities will elute, separate or produce a detectable response. Some impurities may elute earlier, co-elute with the main component, remain retained or respond weakly under the selected detector conditions. Method suitability cannot be established from run length alone.
Ask whether the wash is part of the intended related-substances evaluation or a separate column-cleaning operation. If it is part of the analytical evaluation, the report should make the relevant acquisition, integration and reporting rules identifiable. If it is excluded, request the method rationale or supporting suitability information when necessary for the review.
Programmed gradient time also differs from the time a composition change reaches the column and detector. System dwell volume, flow rate and column hold-up volume affect that timing. There is no universal wash duration that can be judged adequate from a COA alone.
A missing gradient overlay is not itself a failure: many chromatograms do not display one. A missing timetable limits independent assessment but does not prove the laboratory failed to run the method. Request the applicable method details rather than inferring what occurred from the PDF layout.
How should the last peak, plot axis and processing window be reconciled?
First confirm that the chromatogram and peak table refer to the same sample, injection, detector channel and processing result. Then compare the displayed x-axis range with the recorded acquisition duration and the integration window. Where available, inspect the final reported peak's start, retention and end times.
A peak table extending beyond the displayed plot suggests a cropped or mismatched presentation. Request an export that covers the relevant data. An integration-inhibit period can explain why a visible feature has no table entry; whether that exclusion is appropriate depends on the method and reporting rules.
Y-axis scaling can hide small features beside a dominant main peak. An expanded view of the relevant late window can help, but it is not a universal COA requirement. A peak table and documented thresholds may also support review. Distinguish the reporting threshold from the detector's detection limit, quantitation limit and integration settings: these are not interchangeable.
A rising signal at the right edge could reflect an unfinished peak, gradient-related baseline change or another source. Check the complete trace and, where appropriate, blanks or other method controls before assigning an explanation. A complete time window establishes only that the interval was recorded and evaluated; it does not prove that every relevant impurity was detectable or resolved.
If the COA contains both a short assay or area-percent run and a separate related-substances method, assess each against its own purpose and acceptance criteria. Their run times need not be identical.
How should late unspecified peaks and named related substances be interpreted?
Read peak labels alongside the laboratory's identification and reporting conventions. Relative retention time (RRT) can support comparison under a defined method, but RRT alone does not establish chemical identity. A named peak may be supported by reference-standard comparison or other evidence; it is not necessarily just a software-library assignment. Mass spectrometry may support identification, but it is neither the only acceptable approach nor always sufficient for an unambiguous structure assignment.
Keep unidentified features described as unidentified unless the available evidence supports a more specific label. A late signal may arise from a sample component, carryover, contamination or gradient-related effects. Its timing alone does not make it a peptide-related impurity.
Check which peaks enter the calculation, which are excluded and why. The report may distinguish reporting thresholds, disregard limits, specified impurities and unspecified impurities. Request clarification if those definitions are absent. Do not assume that every detected feature must appear in the COA table or that every omitted feature was included in the area-percent denominator.
Compare totals with individual rows using the documented calculation rules, response factors where applicable and rounding conventions. A column labelled 'any unspecified impurity' may be an acceptance limit or a reported maximum rather than a total; establish which before checking the arithmetic.
No late rows in a table can mean no reportable peaks, an excluded time interval, a cropped report or another reporting convention. It is not sufficient evidence on its own. Conversely, late rows show that some signals were captured, not that all possible related substances were captured.
An area-percent result describes relative integrated detector response under stated conditions. Different responses, co-elution, excluded peaks and undetected components can prevent it from representing mass-fraction purity.
What should an Australian laboratory request in the batch documentation?
Start with traceability. Reconcile the lot identifier on the received container and COA with the laboratory sample identifier and relevant analytical report. An internal sample name need not contain the lot number if a documented mapping establishes the connection. A generic name without an accessible mapping is a traceability gap.
For a run-time review, request the method identifier and version, the relevant timetable, the acquisition duration, a chromatogram covering the intended analytical window, the peak table, and the integration and reporting rules. Detector channel, column conditions, acquisition date and processing information may also be needed to interpret the result. Not every detail must be printed on the COA itself; controlled supporting records can provide the necessary evidence.
Where reprocessing affects a reported result, the laboratory should be able to identify the underlying acquisition and explain the revised processing. Request raw data or additional records through the applicable quality agreement when a PDF cannot resolve the question.
Use three separate review questions: does this result belong to the received lot; does the report cover the method's intended evaluation window; and is the method suitable for the analytical claim being made? These questions cannot be answered by a headline percentage alone.
Australian stock location and tracking records concern logistics, not analytical validity. They do not establish run-time completeness, product quality or regulatory status. Resolve material documentation discrepancies according to the receiving laboratory's quality procedures; whether a lot must be held depends on those procedures and the significance of the gap. Research-use labelling and an HPLC report do not establish suitability for human or veterinary use.
Apply this checklist to documented stock
You now have a practical way to read purity figures, method notes, and lot traceability. When you source materials, hold suppliers to that same checklist — ClaraScience issues batch documentation with every order and dispatches from Australian warehouses with Express tracked shipping.
Start with a retail order to review documentation end-to-end, or register for wholesale if you restock multiple compounds.
Frequently asked questions
What is HPLC run-time completeness on a peptide COA?
It is a check that acquisition and processing cover the analytical window required by the applicable method. Compare that window with the recorded duration, displayed chromatogram and integration settings. The full instrument timetable may also include cleaning and re-equilibration steps outside the reporting window.
If the baseline is flat after the main peak, is the run complete?
Not necessarily. Confirm the relevant acquisition and processing windows, plot scale and reporting rules. A flat trace does not establish that all potential impurities eluted, were resolved or were detectable under the method.
Must the wash segment be included in area-percent purity?
Not automatically. A wash may be part of the analytical evaluation or a separate cleaning step. The applicable method should define the reporting window and which peaks enter the calculation. If late-eluting impurity assessment depends on that segment, the supporting data must cover it appropriately.
How does run-time completeness differ from chromatographic purity?
Run-time completeness concerns coverage of the intended analytical interval. Chromatographic area percentage concerns relative integrated detector response within the defined calculation. Neither alone establishes mass-fraction purity, complete impurity coverage or suitability for a particular use.
What should an Australian purchaser request if the chromatogram PDF looks cropped?
Request the acquisition duration, an export covering the relevant analytical interval, the applicable method timetable, the integration window and reporting rules, and a peak table linked to the same sample and result. A cropped PDF may be a presentation issue rather than missing acquisition data.
Does a matching lot number prove the HPLC run was complete?
No. Lot matching supports traceability; run-time coverage and method suitability require separate checks. A documented mapping between the lot and an internal laboratory sample identifier can also provide traceability.
References
- DOI:10.1006/abio.1993.1102 — The Direct Assay of Kinases and Acyl-CoA Synthetases by HPLC: Application to Nucleoside Diphosphate Kinase and Succinyl-CoA Synthetase — Analytical Biochemistry — 1993
- DOI:10.1002/asi.5090180408 — Suggestions on how to read experimental material in information science — American Documentation — 1967
- DOI:10.5694/j.1326-5377.1992.tb137249.x — 13. How to read a journal article — Medical Journal of Australia — 1992
- DOI:10.3897/tdwgproceedings.1.19941 — Documentation about Atlas of Living Australia tools: how to find information — Proceedings of TDWG — 2017
- DOI:10.7816/ulakbilge-05-15-06 — HOW TO BE READ PIAAC RESULTS FOR ADAPTATION TO NEW AGE? — Ulakbilge Dergisi — 2017
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
